Literature DB >> 11095107

Pro islet amyloid polypeptide (ProIAPP) immunoreactivity in the islets of Langerhans.

G T Westermark1, D F Steiner, S Gebre-Medhin, U Engström, P Westermark.   

Abstract

Islet amyloid is typically found in type 2 diabetes mellitus and is believed to participate in the beta cell deterioration. The islet amyloid fibril consists of the 37-amino-acid islet amyloid polypeptide (IAPP) but its pathogenesis is only partly understood. We developed several different rabbit antisera against the flanking peptides of the IAPP precursor (proIAPP) and the proIAPP processing sites in order to study the possible occurrence of unprocessed proIAPP or parts thereof in islet amyloid. We applied these antisera in an immunohistochemical study on, islet amyloid deposits present in a newly generated mouse strain that over-expresses human IAPP but is devoid of mouse IAPP. Male mice of this strain develop severe islet amyloidosis when given a high fat diet. Generally, the antisera showed no immunoreactivity with the amyloid. However, in scattered single beta cells, where amyloid could be seen intracellularly, immunoreactivity with one or more of the antisera co-localized with the amyloid. Although virtually all amyloid in human islets of Langerhans is found extracellularly, we propose that the initial amyloid formation occurs intracellularly, perhaps by not fully processed or folded (pro)IAPP. This amyloid, which may develop rapidly under certain circumstances, probably leads to cell death. If not degraded these amyloid spots may then act as nidus for further amyloid formation from fully processed IAPP, secreted from surrounding beta cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095107     DOI: 10.1517/03009734000000057

Source DB:  PubMed          Journal:  Ups J Med Sci        ISSN: 0300-9734            Impact factor:   2.384


  13 in total

1.  Inhibition of glycosaminoglycan-mediated amyloid formation by islet amyloid polypeptide and proIAPP processing intermediates.

Authors:  Fanling Meng; Daniel P Raleigh
Journal:  J Mol Biol       Date:  2010-12-30       Impact factor: 5.469

Review 2.  Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets?

Authors:  Per Westermark; Arne Andersson; Gunilla T Westermark
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

3.  Blockade of islet amyloid polypeptide fibrillation and cytotoxicity by the secretory chaperones 7B2 and proSAAS.

Authors:  Juan R Peinado; Furqan Sami; Nina Rajpurohit; Iris Lindberg
Journal:  FEBS Lett       Date:  2013-09-13       Impact factor: 4.124

Review 4.  Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?

Authors:  A Clark; M R Nilsson
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

Review 5.  Amyloid in the islets of Langerhans: thoughts and some historical aspects.

Authors:  Per Westermark
Journal:  Ups J Med Sci       Date:  2011-05       Impact factor: 2.384

6.  Drosophila melanogaster as a model system for studies of islet amyloid polypeptide aggregation.

Authors:  Sebastian Wolfgang Schultz; K Peter R Nilsson; Gunilla Torstensdotter Westermark
Journal:  PLoS One       Date:  2011-06-14       Impact factor: 3.240

Review 7.  Amylin at the interface between metabolic and neurodegenerative disorders.

Authors:  Thomas A Lutz; Urs Meyer
Journal:  Front Neurosci       Date:  2015-06-16       Impact factor: 4.677

8.  The ability of insulin to inhibit the formation of amyloid by pro-islet amyloid polypeptide processing intermediates is significantly reduced in the presence of sulfated glycosaminoglycans.

Authors:  Hui Wang; Daniel P Raleigh
Journal:  Biochemistry       Date:  2014-04-18       Impact factor: 3.162

Review 9.  Amyloid deposition in transplanted human pancreatic islets: a conceivable cause of their long-term failure.

Authors:  Arne Andersson; Sara Bohman; L A Håkan Borg; Johan F Paulsson; Sebastian W Schultz; Gunilla T Westermark; Per Westermark
Journal:  Exp Diabetes Res       Date:  2009-03-05

Review 10.  The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.

Authors:  Steven E Kahn; Yi-Chun Chen; Nathalie Esser; Austin J Taylor; Daniël H van Raalte; Sakeneh Zraika; C Bruce Verchere
Journal:  Endocr Rev       Date:  2021-09-28       Impact factor: 25.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.